February 15, 2022 11:08 AM ESTUpdated February 16, 01:44 PM
News Briefing

Biofron­tera will yank shares from Nas­daq; In­tel­lia and ONK col­lab­o­rate on can­cer can­di­dates

Josh Sullivan

Ger­man bio­phar­ma Biofron­tera has de­cid­ed to delist its shares from the Nas­daq and dereg­is­ter its re­port­ing oblig­a­tions with the SEC in an at­tempt to re­duce …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: CEO of Unit­ed­Health in­sur­ance unit shot and killed in New York in what po­lice call ‘a brazen, tar­get­ed ...

Blue­bird and Ver­tex's sick­le cell gene ther­a­pies to kick off new Med­ic­aid ac­cess mod­el

Lil­ly beats No­vo in bell­wether head-to-head weight loss study

As 23andMe strug­gles, an­oth­er ge­net­ic test­ing com­pa­ny bets on drug dis­cov­ery

Mod­er­na CEO de­fends pan­dem­ic prep ef­forts with crit­ics set to en­ter Trump’s ad­min­is­tra­tion

Trade group tells FDA that semaglu­tide is not too 'com­plex' for com­pound­ing

A service from the Financial Times